Reports Q3 revenue $272.3M, consensus $275.4M. “CARVYKTI continues to deliver strong sequential revenue growth, driven by sustained demand and recognition of its unprecedented survival benefit, now supported by five-year progression free data from the CARTITUDE-1 study,” said Ying Huang, CEO. “CARVYKTI remains the market leader in multiple myeloma CAR-T as the only approved therapy for second-line treatment, now with a survival benefit label. With commercial supply from our Tech Lane facility in Belgium now supporting the European market, and our Raritan physical expansion on track for approval by year end, we believe we are poised to achieve CARVYKTI profitability by year-end and company-wide profitability in 2026.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- LEGN Earnings this Week: How Will it Perform?
- Legend Biotech to Showcase Key Research at ASH 2025
- Mitchell Kapoor Highlights Underappreciated Potential and Growth Opportunities for Legend Biotech’s CARVYKTI Amid Market Expansion
- Legend Biotech price target lowered to $60 from $75 at H.C. Wainwright
- Legend Biotech’s CARVYKTI® Receives FDA Approval for Label Update with New Survival Data